Biocom’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.
CEO, Genesis Therapeutics
Evan Feinberg is a scientist and entrepreneur whose lifelong mission is to radically improve the way we discover new medicines. Dr. Feinberg started Genesis Therapeutics, an a16z-funded, AI-driven drug discovery company, to do just that. Genesis originated in cutting-edge deep learning research by Dr. Feinberg in Vijay Pande’s lab at Stanford. During graduate school, Dr. Feinberg co-invented PotentialNet, among several other novel machine learning algorithms, as well as consulted on deep learning for big pharma. Prior to receiving a Ph.D. in Biophysics from Stanford, he received his B.S. in Applied Physics from Yale.